Physician profile
Babu S Kumar
NPI 1295721942
$16,197.72
in general payments reported to CMS, 2019-2025
53 companies · $2,522 in 2025
The $2,522 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,696 · 2020: $1,576 · 2021: $2,208 · 2022: $2,257 · 2023: $2,481 · 2024: $2,458 · 2025: $2,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,461 · Education: $0.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,461.47 |
| Education | $0.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,446.04 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,633.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,432.75 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $1,172.99 | 2019-2024 | |
| Glaxosmithkline, LLC. | $1,086.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,070.88 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $768.63 | 2019-2025 | Otezla, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $594.09 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $437.98 | 2019-2025 | Zoryve |
| Abbvie INC. | $412.12 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $398.81 | 2019-2023 | Dificid |
| Astellas Pharma US INC | $378.75 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $315.59 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $313.32 | 2021-2023 | |
| Amarin Pharma, INC. | $306.63 | 2019-2023 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babu Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.